Emmessar Biotech and Nutrition Ltd

Thu 3/09/2026,11:42:0 | BSE : EMMESSA

₹24.28-1.12 (-4.41%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 25.98

Previous Close

₹ 25.40

Volume

513

Mkt Cap ( ₹ Cr)

₹ 12.13

High

₹ 25.98

Low

₹ 23.15

52 Week High

₹ 42.75

52 Week Low

₹ 18.42

Book Value Per Share

₹ 16.51

Dividend Yield

₹ 0.00

Face Value

₹₹10.00

What's Your Call?

Collective community sentiment on Emmessar Biotech and Nutrition Ltd

Your Vote -

Buy

66.67%

Hold

16.67%

Sell

16.67%

66.67%

6 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Emmessar Biotech and Nutrition Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Emmessar Biotech - Newspaper Add For AGM

    27 Aug 2026, 2:40PM Please refer attachment
  • Emmessar Biotech - Newapaper Add

    8 Aug 2026, 2:18PM Please refer attachment
  • Emmessar Biotech - Unaudited Financial Results For The Quarter Ended June 30, 2026

    7 Aug 2026, 2:06PM Please refer attachement
  • Emmessar Biotech - Board Meeting Outcome for For Unaudited Financial Results For The Quarter Ending June 30, 2026

    7 Aug 2026, 2:01PM Please refer attachement
  • Emmessar Biotech - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2026

    1 Aug 2026, 3:52PM Emmessar Biotech & Nutrition Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to
  • Emmessar Biotech - Newspaper Add For Relodgement Of Shares

    1 Aug 2026, 3:50PM please refer attachment
  • Emmessar Biotech has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    14 Jul 2026, 9:51AM As of June 2026, 59.53% is owned by Indian Promoters and 40.47% by Public. <p align=justify> Top five Promoters holding highest number of shares of Em
  • Emmessar Biotech - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    13 Jul 2026, 10:59PM Please refer attachment

Key fundamentals

Evaluate the intrinsic value of Emmessar Biotech and Nutrition Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 8.1148 7.7081 7.5118 6.7467 6.1689
Liabilities 8.1148 7.7081 7.5118 6.7467 6.1689
Equity 4.9961 4.9961 4.9961 4.9961 4.9961
Gross Profit -1.3536 -0.9523 -1.0819 -0.6902 -0.8948
Net Profit 0.4359 0.3162 0.7496 0.5038 0.4753
Cash From Operating Activities -0.3491 0.2238 0.6445 0.3762 2.2698
NPM(%) 117.55 51.75 135.01 49.43 130.25
Revenue 0.3708 0.6109 0.5552 1.0192 0.3649
Expenses 1.7244 1.5632 1.6371 1.7094 1.2598
ROE(%) 5.28 3.83 9.09 6.1 5.76

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Emmessar Biotech and Nutrition Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Nitta Gelatin India Ltd 1605.70 -0.39 14.16 23.06 1071.07 0.43
Sharda Cropchem Ltd 779.30 0.11 11.21 229.16 754.66 1.93
Ram Minerals and Chemicals Ltd 0.49 0.00 49.00 522.71 -0.09 0.00
Amines and Plasticizers Ltd 180.30 -1.45 25.40 139.75 331.99 0.28

Company Info

The Company was incorporated in the state of Maharashtra as a Public Limited Company on 17th March 1992 and certificate of commencement of business dt. 20.3.92 was obtained from Registrar of Companies, Maharashtra, Bombay. The Registered office of the Company is situated at Plot No. T-3/2, MIDC Area, P.O. Box No. 39, Taloja - 410 208, Raigad (Dist), Maharashtra. The Company has revalued the land admeasuring 16,126 Sq. meters, in the month of January 1994, since the MIDC rate per Sq. meter had increased to Rs. 550/- from Rs. 200/- at the time of its purchase in the month of October 1992. The value of the land is now recorded at Rs.88,71,300/- instead of Rs. 32,52,400/ - which was the cost price, vide the valuation report of D K Nagarseth & Associates( Approved Valuer No. F-2087) dated 4th, Jan., 1994. MAIN OBJECTS OF THE COMPANY The main objects to be pursued by the Company on its incorporation as stated in its Memorandum of Association are: To formulate, develop, manipulate, process, import, export, buy, sell, or otherwise deal in all Organic and Inorganic chemicals, Fine chemicals, Heavy chemicals, Performance chemicals, Agro-chemicals, all kinds of organic and Inorganic pigments, colour, Dyestuffs and their intermediates, all kinds of Organic and Inorganic acids and alkalies, Drugs, Medicines and their intermediates, Silicon and Phosphorus based chemicals and byproducts thereof and products to be made there from, and all tools of Bio- Technology. SUBSIDIARIES OF THE COMPANY The Company does not have any subsidiaries. 2005 -Emmessar Biotech enters into strategic alliance with Twilight Mercantiles 2007 -Emmessar Biotech has designated E-mail ID for Investor Complaints: investors@ebnl.in 2008 -Emmessar Technologies Private Ltd became Emmessar Technologies Ltd (ETL) -RESQ, an unfailing solution for treating all types of burns from heat & radiation was launched. -Cute N Comely, a premier topical application with protective & therapeutic properties to ensure an optimal & natural skin rejuvenation process was launched. 2009 -Frejomus tablets was launched to help mitigate joint pains that restrict movement for the middle and old aged people. 2010 -Sepecer, a reliable solution for neurological and physiological health for the middle ages and beyond was launched. 2011 -Psoribalm was launched to meet the long standing demand for a harmless & reliable treatment for the most obstinate & dangerous skin disease - Psoriasis. 2016 -Over 30 newly developed products to meet a spectrum of healthcare needs ready to be launched progressively from mid 2016 onwards.

The Company was incorporated in the state of Maharashtra as a Public Limited Company on 17th March 1992 and certificate of commencement of business dt. 20.3.92 was obtained from Registrar of Companies, Maharashtra, Bombay. The Registered office of the Company is situated at Plot No. T-3/2, MIDC Area, P.O. Box No. 39, Taloja - 410 208, Raigad (Dist), Maharashtra. The Company has revalued the land admeasuring 16,126 Sq. meters, in the month of January 1994, since the MIDC rate per Sq. meter had increased to Rs. 550/- from Rs. 200/- at the time of its purchase in the month of October 1992. The value of the land is now recorded at Rs.88,71,300/- instead of Rs. 32,52,400/ - which was the cost price, vide the valuation report of D K Nagarseth & Associates( Approved Valuer No. F-2087) dated 4th, Jan., 1994. MAIN OBJECTS OF THE COMPANY The main objects to be pursued by the Company on its incorporation as stated in its Memorandum of Association are: To formulate, develop, manipulate, process, import, export, buy, sell, or otherwise deal in all Organic and Inorganic chemicals, Fine chemicals, Heavy chemicals, Performance chemicals, Agro-chemicals, all kinds of organic and Inorganic pigments, colour, Dyestuffs and their intermediates, all kinds of Organic and Inorganic acids and alkalies, Drugs, Medicines and their intermediates, Silicon and Phosphorus based chemicals and byproducts thereof and products to be made there from, and all tools of Bio- Technology. SUBSIDIARIES OF THE COMPANY The Company does not have any subsidiaries. 2005 -Emmessar Biotech enters into strategic alliance with Twilight Mercantiles 2007 -Emmessar Biotech has designated E-mail ID for Investor Complaints: investors@ebnl.in 2008 -Emmessar Technologies Private Ltd became Emmessar Technologies Ltd (ETL) -RESQ, an unfailing solution for treating all types of burns from heat & radiation was launched. -Cute N Comely, a premier topical application with protective & therapeutic properties to ensure an optimal & natural skin rejuvenation process was launched. 2009 -Frejomus tablets was launched to help mitigate joint pains that restrict movement for the middle and old aged people. 2010 -Sepecer, a reliable solution for neurological and physiological health for the middle ages and beyond was launched. 2011 -Psoribalm was launched to meet the long standing demand for a harmless & reliable treatment for the most obstinate & dangerous skin disease - Psoriasis. 2016 -Over 30 newly developed products to meet a spectrum of healthcare needs ready to be launched progressively from mid 2016 onwards.

Parent Organisation

Emmessar Biotech & Nutrition Ltd.

Founded

17/03/1992

Managing Director

Mr.Srinivasa Raghavan Mathurakavi Ayyangar

NSE Symbol

FAQ